Builds Team of Experts to Complete New Global Drug Development
Experts in Pain-Related Clinical
Development and Pharmaceutical Marketing Have Joined
Nov 9, 2017 –
SEOUL, Korea - ViroMed (KOSDAQ 084990), a biotech company developing novel biologics,
announced on November 7th that it has built a global team of experts to add
momentum to the global development of VM202 by recruiting Dr. William Schmidt, Dr.
Cathryn Carroll, and Dr. Marie-Laure Nevoret.
Schmidt, Ph.D., is now responsible for overseeing ViroMed’s U.S. clinical
trials evaluating VM202,
a proprietary, DNA-based biopharmaceutical product
targeting DPN, PAD and ALS, as Director of the Global Clinical Development Unit.
Dr. Schmidt has more than 30 years of experience in developing pain-related medicines
with special expertise in clinical studies and regulation. He is also President
of NorthStar Consulting, an agency that provides consulting services to
pharmaceutical and bioengineering companies around the world on pre-clinical
and clinical studies for innovative pain medications. Dr. Schmidt has also served
as President at Catalina Pharma, Vice President for clinical development at EicOsis,
and Chief Medical Officer at Ensysce Biosciences.
Nevoret, MD, is a surgeon and clinical researcher specializing in diabetic periphery
neuropathy (DPN), whose role at ViroMed is to support and operate VM202 clinical
trials in the U.S with Dr. Schmidt.
Dr. Cathy Carroll,
Ph.D., has joined ViroMed’s Strategic Business Development Team to strengthen
the team’s capability of global marketing and business development while overseeing
VM202’s licensing-out process. Dr. Carroll is leading the company’s global
marketing and communication by pursuing a variety of business partnerships and licensing-out
while introducing new pipelines and establishing pre-commercialization
strategies of VM202 in market entry, pricing, and public and investor relations.
With B.S. in Pharmacy, MBA, and Ph.D. in Economics, Dr. Carroll’s expertise spans
various fields and disciplines. She worked for a number of companies in the pharmaceutical
field, serving as Senior Director for Commercial Consulting and Market Access
at Xcenda, Associate Director for Global Health Economics & Outcomes
Research at Teva Pharmaceutical, and Director of Pharmacy at Comprehensive
Dr. Marie-Laure Nevoret,
Dr. Cathy Carrol
ViroMed CEO Yongsoo
Kim explained the significance of securing an additional lineup of global experts
in clinical development and business development.
“Multinational pharmaceutical companies have multi-faceted strategies to
position themselves with a competitive edge in the market, not only by
designing clinical development strategies based on FDA regulations, but also conducting
pricing analysis and establishing marketing strategies. We have decided that,
in order to complete the development of VM202 as a global novel medicine, ViroMed
needs a global marketing strategy that takes account of the full range of
clinical development, BLA and market launch all together, which is why we have these
experts on board."